Great article, covers a lot of ground.<p>The rescheduling benefits may apply to the UK, but aren't particularly important to work on for the US.<p>In the US, access to research funding is a far larger issue than scheduling. The main benefit of rescheduling would likely be through its indirect benefits on access to funding, possibly from government agencies like the NIMH.<p>Also, both psilocybin and MDMA are in or beginning FDA Phase 3 trials, for likely approval ~2023 and 2021 respectively, after which they will be automatically rescheduled. So if you're in the US and you want to contribute to rescheduling, the way to do it is to fund the Phase 3 research via Heffter and MAPS. (It's possible that psilocybin and MDMA will be rescheduled, but that magic mushrooms and ecstasy will remain schedule I, but I don't think that's particularly worse based on my understanding.)<p>Source: I’ve talked with multiple researchers who are studying psychedelics.<p>Also, I recommend reading or listening to the book Acid Test if anyone here would like to learn more.
On a related note:<p>It is absolutely shocking to me that research into psychedelics isn't swamped with funding. I'd imagine that some wealthy people must find this stuff extremely intriguing - Yuri Milner is spending $100 million on space exploration, and a psilocybin phase 3 research trial needs ~$10 million and finds it really hard to raise money?<p>Psychedelics have extremely high therapeutic potential, and are also just interesting in a similar same way as space exploration is interesting.<p>And as diogenescynic noted elsewhere, it's even more shocking that we as a society put up with it.